

1 **Quantification and prognostic significance of interferon- $\gamma$  secreting SARS-CoV-2**  
2 **responsive T cells in hospitalised patients with acute COVID-19**

3 Daniel Pan<sup>1,2\*</sup>, Jee Whang Kim<sup>1,3\*</sup>, Joshua Nazareth<sup>1,2\*</sup>, Sara Assadi<sup>2</sup>, Adam Bellass<sup>2</sup>, Jack Leach<sup>4</sup>,  
4 James G Brosnan<sup>4</sup>, Adam Ahmed<sup>4</sup>, Fleur Starcevic<sup>2</sup>, Shirley Sze<sup>5</sup>, Christopher A Martin<sup>1,2</sup>,  
5 Caroline M Williams<sup>1,6</sup>, Michael R Barer<sup>1,6</sup>, Amandip Sahota<sup>2</sup>, Prashanth Patel<sup>7</sup>, Andrea  
6 Tattersall<sup>8</sup>, Andrea Cooper<sup>1,9</sup>, Manish Pareek<sup>1,2‡</sup>, Pranabashis Haldar<sup>1,3‡</sup>

7 \*Joint first authorship

8 ‡Joint senior authorship

9 <sup>1</sup>Department of Respiratory Sciences, University of Leicester, United Kingdom

10 <sup>2</sup>Department of Infectious Diseases and HIV Medicine, University Hospitals of Leicester NHS  
11 Trust, United Kingdom

12 <sup>3</sup>Respiratory Biomedical Research Centre, University of Leicester, United Kingdom

13 <sup>4</sup>University of Leicester Medical School, United Kingdom

14 <sup>5</sup>Department of Cardiovascular Sciences, University of Leicester, United Kingdom

15 <sup>6</sup>Department of Microbiology, University Hospitals of Leicester NHS Trust, United Kingdom

16 <sup>7</sup>Department of Chemical and Metabolic Diseases, University Hospitals of Leicester NHS Trust,  
17 United Kingdom

18 <sup>8</sup>Oxford Immunotec Ltd, United Kingdom

19 <sup>9</sup>Trudeau Institute, Saranac Lake, New York, United States of America

20

21

22 Word Count: 2,128

23 Abstract word count: 148

24

25

26 **Abstract**

27 Little is known about T-cell responses during acute coronavirus disease-2019 (COVID-19). We  
28 measured T-cell interferon gamma (IFN- $\gamma$ ) responses to spike 1 (S1), spike 2 (S2), nucleocapsid  
29 (N) and membrane (M) SARS-CoV-2 antigens using the T-SPOT<sup>®</sup> *Discovery* SARS-CoV-2 assay, a  
30 proven EliSPOT technology, in 114 hospitalised adult COVID-19 patients and assessed their  
31 association with clinical disease phenotype. T-SPOT<sup>®</sup> *Discovery* SARS-CoV-2 responses were  
32 detectable within 2 days of a positive PCR and did not correlate with vaccination status or  
33 symptom duration. Higher responses to S1 protein associated with a higher symptom burden,  
34 and serum IL-6 levels. Despite treatment with dexamethasone this subgroup was also at greater  
35 risk of requiring continuous positive airway pressure (CPAP) in the days following sampling.  
36 Higher T-cell responses measured using T-SPOT<sup>®</sup> *Discovery* SARS-CoV-2 associate with  
37 progressive disease in acute COVID-19 disease and may have utility as a prognostic biomarker  
38 that should be evaluated in larger cohorts.

39

40 **Introduction**

41

42 The clinical assessment of patients presenting to hospital with Coronavirus Disease-2019  
43 (COVID-19) can be difficult. In particular, patients can appear to be well on initial assessment,  
44 but deteriorate rapidly during their hospital stay.<sup>1</sup> Measurement of the T-cell response during  
45 acute COVID-19 may help to predict disease severity.<sup>2</sup> Current studies have demonstrated high  
46 frequency of SARS-CoV-2-specific T-cell responses in individuals who have recovered from  
47 severe COVID-19 compared those who had mild COVID-19.<sup>3</sup> T-cell immunity has also been  
48 found to be important in long-term protection against SARS-CoV-2 and studies indicate  
49 dissociation between T-cell and neutralizing antibody responses during convalescence.  
50 However, the T-cell response during acute disease and its association with humoral immunity  
51 remains poorly characterized.

52 Here we investigated the systemic T-cell response during acute SARS-CoV-2 infection in  
53 a hospitalised cohort of patients with COVID-19, using a functional T-cell assay developed to  
54 measure T-cell responses to four antigenic domains of SARS-CoV-2. We hypothesized that  
55 systemic T-cell responses in acute COVID-19 disease would be heterogeneous and associate  
56 with interval from symptom onset, prior vaccination status and disease severity.

57

58 **Results**

59 *Patient recruitment and characteristics*

60 Between 8<sup>th</sup> February and 8<sup>th</sup> March 2021, 114 patients were prospectively recruited, of which  
61 104 patients were admitted to hospital with a primary diagnosis of acute COVID-19 disease. The  
62 remaining 10 patients acquired SARS-CoV-2 in hospital. These participants were negative on  
63 nasopharyngeal PCR swab at the time of hospital admission for other reasons, and developed a  
64 positive PCR during their hospital stay that was identified as part of screening undertaken for  
65 infection control. Table 1 shows participant demographic data. The median age was 64 (IQR  
66 52-78). Most participants were male (n=69, 61%) and of White ethnicity (n=89, 79%). 102 (91%)  
67 were symptomatic (fever, cough, breathlessness, anosmia) at time of sampling. 88 (79%) had  
68 infiltrates on their admission chest x-ray. 31% of patients had received one dose of either the  
69 Pfizer BioNTech or Oxford AstraZeneca vaccine (n=36, 31%) in the weeks prior to acute  
70 infection; 29 had received their vaccine 2 weeks or longer prior to admission. In keeping with  
71 the UK vaccine policy, this was an older aged cohort. The median duration of symptoms prior to  
72 sampling was 10 days (IQR 7 to 15). Most patients had been treated with dexamethasone  
73 (n=73, 64%); Almost all patients were antibody positive at time of sampling (n=95, 93%).

#### 74 *Association between T-SPOT panels and antibody responses*

75 Valid T-SPOT assay readings were obtained in 87 patients (76%). In the remainder, the assay  
76 could not be performed due to an insufficient number of peripheral blood mononuclear cells in  
77 the samples collected. These patients were more lymphopenic (median lymphocyte count in  
78  $0.8 \times 10^9$  cells/ml (IQR 0.4 to 1.1); compared with  $1.3 \times 10^9$  cells/ml (IQR 1.0 to 1.7),  $p < 0.001$ ). In  
79 the 87 subjects with a measurable T-cell response, the responses to the spike protein antigens  
80 S1 and S2 were most sensitive, being positive in the highest proportion of participants (Table 3)

81 and at the greatest amplitude. The median T-SPOT for S1 was 5 spots (IQR 2 to 54); S2: 5 spots  
82 (IQR 2 to 22); Nucleocapsid: 3 spots (IQR 0 to 7); Membrane: 3 spots (IQR 1 to 10). Table 2  
83 shows the associations between different T-cell panels and combined IgG/IgM for the S1.  
84 Strong correlation was observed between the response to S1 and responses to the other three  
85 antigens. However, there was little concordance between T-SPOT responses and the antibody  
86 assay. We observed no association of T-cell responses with either prior vaccination status or  
87 interval after symptoms onset. The T-SPOT assay was positive in the 12 asymptomatic patients  
88 and could be detected within 3 days of a positive PCR test. In the 10 nosocomial patients, T-  
89 SPOT assays were also detectable 16 days after an initially positive PCR test.

#### 90 *Relationship between T-SPOT responses and markers of disease severity*

91 84 (73%) participants received oxygen during hospitalisation; a fifth required continuous  
92 positive airway pressure (CPAP) in the days following blood sampling (n=24, 21%) for  
93 progressive respiratory failure. None required mechanical ventilation. 7 (6%) study participants  
94 died within 28 days of hospital admission. Table 3 shows the relationship between clinical  
95 variables and responses to all four antigens of the T-SPOT assay. In general, patients with higher  
96 T-cell responses to S1 protein were more likely to be symptomatic, have raised IL-6 levels,  
97 receive dexamethasone for COVID-19 and receive CPAP prospectively (Figure 1).

98

#### 99 **Discussion**

100 Our study is the first to evaluate T-cell responses using the T-SPOT assay in hospitalised patients  
101 with acute COVID-19. We found that T-cell responses appeared as early as two days after  
102 symptom onset in early COVID-19, and can be positive in the context of a negative combined  
103 antibody assay. Second, in a hospitalised cohort, we found T-cell responses to be similar  
104 between vaccinated and unvaccinated participants. Finally, we found that higher T-cell  
105 responses, predominantly those to S1 appear to be related to a more severe disease  
106 phenotype.

107 Previous studies have assessed the utility of the T-SPOT assay in convalescent patients  
108 and found that T-SPOT responses to the same proteins in this study were seen in the absence of  
109 anti-Spike IgG on long-term follow-up. We found similar levels of discordance in patients with  
110 acute COVID-19, highlighting the potential of the T-SPOT assay to pick up immunological  
111 responses in COVID-19 positive patients where antibody responses are negative. T-SPOT  
112 responses were also much higher in studies in convalescent individuals, highlighting clear  
113 differences in the kinetics of the T-cell response compared with antibody response over time  
114 after infection and vaccination.<sup>4,5</sup>

115 We provide real-world data on the T-cell response of patients who had received one  
116 dose of the Pfizer BioNTech or Oxford AstraZeneca vaccine prior to developing COVID-19  
117 requiring hospitalisation. We did not observe amplification of the T-cell response in this group,  
118 compared with the unvaccinated population. This could reflect the design of current vaccines,  
119 which focus on generating a neutralizing antibody response rather than T-cell response,  
120 measurement of T-cell responses in a primarily older cohort where there is immunosenescence

121 or may reflect insufficient time for the vaccines to induce robust T-cell immunity, despite the  
122 fact that the majority of our patients had their first dose 2 weeks or longer prior to admission

123         The presence of early T-cell responses during acute COVID-19 has been shown in smaller  
124 cohorts using different assays. Tan and colleagues examined the dynamic changes in the  
125 immunological response in 12 patients with COVID-19 and also found both antibody responses  
126 and interferon- $\gamma$ -SARS-CoV-2 specific T cells to be present as early as 2 days from symptom  
127 onset<sup>6</sup>, in keeping with the findings in this study. It appears that immune activation after  
128 infection with SARS-CoV-2 occurs rapidly, before the virus can evade or suppress recognition,  
129 even in the absence of previous infection or vaccination.

130         We found an association between higher T-SPOT responses (especially S1) and  
131 increasing disease severity at the time of sampling, as evidenced by higher IL-6 levels and  
132 prospective need for CPAP. It is not clear whether these T-cell responses are protective or  
133 deleterious. A protective role for the higher T-cell responses in severe disease is supported by  
134 the low 28-day mortality rate in this cohort. However, it is possible that the elevated T-cell  
135 responses are a marker of immune hyperstimulation generating cytokine over-production and  
136 cell death.<sup>7</sup> Studies comparing T cell phenotype and cytokine levels are needed to resolve this  
137 question.

138         Our study was limited by size and sociodemographic heterogeneity, with a variable  
139 proportion exposed to immunomodulatory interventions, including dexamethasone treatment  
140 and a prior history of receiving one dose of a two-dose vaccination regimen. In contrast to  
141 studies on convalescent patients, a quarter of samples from our cohort could not be processed

142 to perform the T-SPOT assay due to inadequate cell numbers and is likely a consequence of the  
143 lymphopenia that occurs in acute COVID-19; future studies using the assay can overcome this  
144 by taking larger quantities of blood. Despite this, our study demonstrates that T-cell responses  
145 to the S1 antigen, measured using the T-SPOT assay appear early in infection and associate with  
146 objective measures of disease severity - these observations warrant further investigation in  
147 other cohorts. Our findings also support the need for larger studies to investigate the kinetics of  
148 T-cell responses in acute infection and to build understanding of how these responses influence  
149 short and long term prognosis.

150

## 151 **Methods**

152

### 153 *Participant recruitment*

154 We conducted a prospective observational cohort study of hospitalised and nosocomially  
155 infected adult patients at University Hospitals of Leicester NHS Trust. Patients were eligible if  
156 they were 16 years or over, tested positive for SARS-COV-2 on nasopharyngeal RT-PCR using the  
157 hospital assay, with no previous history or record of infection and no existing conditions or  
158 treatments associated with T cell immunodeficiency.

### 159 *Blood sampling*

160 One 10ml lithium heparin anticoagulated blood for T-cell functional assay and one 6ml blood  
161 anticoagulated using EDTA to measure antibody response was taken from each study  
162 participant within 24 hours of a positive routine PCR test. Serology was performed using the



163 commercially available SARS-CoV-2 Total Assay manufactured by Siemens, which detects IgG  
164 and IgM to the S1 RBD antigen and gave a qualitative result.<sup>8</sup>

165 *T-SPOT assay*

166 To measure T cell responses, we used the T-SPOT<sup>®</sup> Discovery SARS-CoV-2 kit (T-SPOT), which  
167 uses an ELISpot technology to detect IFN- $\gamma$  release from T cells after exposure to four SARS-  
168 CoV-2 peptides antigens: Spike protein S1 and S2 domains, Membrane and Nucleoprotein  
169 peptides.<sup>9</sup> In brief, cells were isolated and washed from peripheral blood and SARS-CoV-2  
170 responsive T cell numbers are enumerated using a T-SPOT Discovery SARS-CoV-2 tests, which  
171 are based on the same proven analytical platform as the T-SPOT<sup>®</sup>.*TB* (tuberculosis) kit also  
172 manufactured by Oxford Immunotec. Peripheral blood mononuclear cells (PBMCs) were treated  
173 with T-Cell *Xtend*<sup>®</sup> reagent (Oxford Immunotec Ltd) prior to isolated from whole blood.

174

175 T cells isolated from whole blood stored overnight appear to show reduced responses to  
176 stimulation with antigens in ELISPOT assays, but this is primarily due to contaminating cell  
177 populations in the PBMC layer. The T-Cell *Xtend* reagent contains bispecific monoclonal  
178 antibodies which are directed against cell surface markers on selected white blood cells and  
179 glycoprotein A on the red blood cells. The T-Cell *Xtend* reagent cross-links the selected white  
180 blood cells with the red blood cells, which increases the density of the selected cells. When a  
181 density gradient is applied during FICOLL extraction, the selected white blood cells remain  
182 separated in the red blood cell layer away from the PBMC layer. Non-selected cells, including T  
183 cells and antigen presenting cells, are contained in the PBMC layer.

184

185 Briefly, 10 mL of blood was treated with 250  $\mu$ L T-Cell *Xtend* reagent After addition of  
186 reagent, tubes were inverted five times and left to stand at room temperature for 20 minutes  
187 before starting the isolation of PBMCs. PBMCs were isolated by standard ficoll-hypaque  
188 density-gradient centrifugation from heparinized blood samples. The PBMC were washed twice  
189 with RPMI-1640 medium, counted with an automated haematology analyser and adjusted in  
190 AIM V medium such that each of four wells of the assay plate contained 250,000 PBMC.

191  
192 The cells were incubated at 37 °C and 5% CO<sub>2</sub> for 16–20 h with medium (negative  
193 control), phytohemagglutinin (positive control) and peptides. After 16-20 hours incubation, the  
194 wells were washed and developed using a conjugated secondary antibody that bound to any  
195 IFN- $\gamma$  captured on the membrane. After washing to remove unbound IFN- $\gamma$ , substrate was  
196 added to produce dark spots of insoluble precipitate indicating areas of IFN- $\gamma$  secretion from T  
197 cells. These spot forming cells (SFCs) were counted using an automated ELISpot plate reader  
198 (CTL, Shaker Heights, OH) and manually verified.

199  
200 Each subject had to display a satisfactory response to the positive control (> 20 spots  
201 and/or saturation of the well) and a low spot number in the negative control ( $\leq$  10 spots of the  
202 well); otherwise, the test was classified as indeterminate.

203  
204 *Clinical data and ethical approval*

205 Routine clinical, radiological, laboratory and demographic data at the time of sampling  
206 was collected and prospective outcomes during admission including requirement for CPAP,

207   invasive ventilation and 28 day mortality, were recorded. The study had ethical approval from  
208   the West Midlands Research Ethics Committee (REC Reference 20/WM/0153).

209   *Statistical analysis*

210           Continuous variables are expressed as median and interquartile range (IQR). Categorical  
211   variables are displayed as numbers and percentages (%). Pearson's Chi-squared and Fisher's  
212   exact row test was used to compare categorical variables between groups. Student's *t*-test and  
213   Kruskal-Wallis test were used to compare continuous variables between groups depending on  
214   the normality of distribution. We chose to examine the relationship between increasing T-SPOT  
215   responses in the four panels separately in relation to clinical variables. The association between  
216   different T-SPOT panels was assessed using Pearson's correlation coefficient; association  
217   between T-SPOT panels and antibody response was assessed using the Kappa statistic.

218           All analyses were performed using STATA version 14.2 (StataCorp United States) and  
219   Excel version 2016 (Microsoft, Redmond, United States). A *p*-value <0.05 was considered to be  
220   statistically significant.

221


222 **References**

- 223 1. Sze, S. *et al.* Variability, but not admission or trends in NEWS2 score predicts clinical  
224 outcome in elderly hospitalised patients with COVID-19. *J. Infect.* **82**, 159–198 (2021).
- 225 2. Sabbaghi, A. *et al.* Role of  $\gamma\delta$  T cells in controlling viral infections with a focus on  
226 influenza virus: implications for designing novel therapeutic approaches. *Virology* **17**, 1–18  
227 (2020).
- 228 3. Sekine, T. *et al.* Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or  
229 Mild COVID-19. *Cell* **183**, 158-168.e14 (2020).
- 230 4. Wyllie, D. *et al.* SARS-CoV-2 responsive T cell numbers and anti-Spike IgG levels are both  
231 associated with protection from COVID-19: A prospective cohort study in key workers.  
232 *medrxiv* (2021).
- 233 5. Clarke, C. L. *et al.* Longevity of SARS-CoV-2 immune responses in hemodialysis patients  
234 and protection against reinfection. *Kidney Int.* **99**, 1470–1477 (2021).
- 235 6. Tan, A. T. *et al.* Early induction of functional SARS-CoV-2-specific T cells associates with  
236 rapid viral clearance and mild disease in COVID-19 patients. *Cell Rep.* **34**, (2021).
- 237 7. McElvaney, O. J., Curley, G. F., Rose-John, S. & McElvaney, N. G. Interleukin-6: obstacles  
238 to targeting a complex cytokine in critical illness. *Lancet Respir. Med.* **9**, 643–654 (2021).
- 239 8. Ainsworth, M. *et al.* Performance characteristics of five immunoassays for SARS-CoV-2: a  
240 head-to-head benchmark comparison. *Lancet Infect. Dis.* **20**, 1390–1400 (2020).


- 241 9. Abubakar, I. *et al.* Two interferon gamma release assays for predicting active  
242 tuberculosis: The UK PREDICT TB prognostic test study. *Health Technol. Assess. (Rockv)*.  
243 **22**, 1–95 (2018).

244


S1



S2



Nucleocapsid



Membrane

